Foresight Group Ltd Liability Partnership Boosts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Foresight Group Ltd Liability Partnership raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 43.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,750 shares of the medical research company's stock after buying an additional 534 shares during the period. Thermo Fisher Scientific accounts for about 0.5% of Foresight Group Ltd Liability Partnership's investment portfolio, making the stock its 23rd biggest position. Foresight Group Ltd Liability Partnership's holdings in Thermo Fisher Scientific were worth $908,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Legacy Investment Solutions LLC acquired a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at $26,000. Peterson Financial Group Inc. acquired a new stake in shares of Thermo Fisher Scientific during the third quarter worth about $27,000. Decker Retirement Planning Inc. bought a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $43,000. HWG Holdings LP acquired a new position in Thermo Fisher Scientific in the 2nd quarter worth $50,000. Finally, RPg Family Wealth Advisory LLC bought a new position in shares of Thermo Fisher Scientific during the third quarter worth about $50,000. 89.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

TMO has been the topic of several recent research reports. Evercore ISI lowered their price target on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. Morgan Stanley reduced their price objective on shares of Thermo Fisher Scientific from $670.00 to $647.00 and set an "overweight" rating for the company in a research report on Monday, January 13th. Royal Bank of Canada lowered their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. Bernstein Bank lifted their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a "market perform" rating in a research note on Tuesday, October 22nd. Finally, Robert W. Baird reduced their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating on the stock in a report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $648.95.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the sale, the executive vice president now directly owns 16,663 shares of the company's stock, valued at $9,333,946.08. This trade represents a 1.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the firm's stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the sale, the senior vice president now owns 12,736 shares of the company's stock, valued at $7,134,197.76. This trade represents a 13.57 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,150 shares of company stock valued at $25,954,465. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Down 0.4 %

Shares of NYSE:TMO traded down $1.99 during mid-day trading on Friday, reaching $559.72. 2,134,669 shares of the company's stock were exchanged, compared to its average volume of 1,426,114. The firm has a market capitalization of $214.09 billion, a price-to-earnings ratio of 35.09, a PEG ratio of 3.59 and a beta of 0.76. The business's fifty day moving average price is $529.80 and its 200-day moving average price is $567.97. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business's quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the company posted $5.69 EPS. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were paid a $0.39 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific's dividend payout ratio is presently 9.78%.

Thermo Fisher Scientific announced that its Board of Directors has initiated a share buyback plan on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board believes its stock is undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.